Re: Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial

被引：1

作者：

Sonpavde, Guru ^{[1
,2
]}

Pal, Sumanta ^{[3
]}

机构：

[1] Univ Alabama UAB, Sch Med, Hematol Oncol Sect, Dept Med, Birmingham, AL USA

[2] Vet Affairs Med Ctr, Birmingham, AL USA

[3] City Hope Comprehens Canc Ctr, Dept Med, Hematol Oncol Sect, Duarte, CA USA

来源：

EUROPEAN UROLOGY | 2016年 / 70卷 / 01期

关键词：

CANCER;

D O I：

10.1016/j.eururo.2016.03.057

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：203 / 203

页数：1

共 43 条

[31] Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268-77 A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma
Singla, Nirmish
Margulis, Vitaly
EUROPEAN UROLOGY, 2021, 79 (01) : E28 - E28
[32] Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial (vol 21, pg 851, 2020)
Frumovitz, M.
Obermair, A.
Coleman, R. L.
LANCET ONCOLOGY, 2020, 21 (07): : E341 - E341
[33] A multicentre, international, randomised, open-label phase 3 trial of avelumab plus best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
Powles, T.
Grivas, P.
Aragon-Ching, J. B.
Faroun, Y.
Kessler, E. R.
Tomita, Y.
Chakrabarti, D.
Laliberte, R. J.
Shnaidman, M.
Petrylak, D.
ANNALS OF ONCOLOGY, 2016, 27
[34] Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Pal, Sumanta Kumar
Albiges, Laurence
Tomczak, Piotr
Suarez, Cristina
Voss, Martin H.
de Velasco, Guillermo
Chahoud, Jad
Mochalova, Anastasia
Procopio, Giuseppe
Mahammedi, Hakim
Zengerling, Friedemann
Kim, Chan
Osawa, Takahiro
Angel, Martin
Gupta, Suyasha
Khan, Omara
Bergthold, Guillaume
Liu, Bo
Kalaitzidou, Melania
Huseni, Mahrukh
Scheffold, Christian
Powles, Thomas
Choueiri, Toni K.
LANCET, 2023, 402 (10397): : 185 - 195
[35] Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit, Rebecca
Lisyanskaya, Alla
Fedenko, Alexander
Dvorkin, Mikhail
de Melo, Andreia Cristina
Shparyk, Yaroslav
Rakhmatullina, Irina
Bondarenko, Igor
Colombo, Nicoletta
Svintsitskiy, Valentyn
Biela, Luciano
Nechaeva, Marina
Lorusso, Domenica
Scambia, Giovanni
Cibula, David
Poka, Robert
Oaknin, Ana
Safra, Tamar
Mackowiak-Matejczyk, Beata
Ma, Ling
Thomas, Daleen
Lin, Kevin K.
McLachlan, Karen
Goble, Sandra
Oza, Amit M.
LANCET ONCOLOGY, 2022, 23 (04): : 465 - 478
[36] Re: Thomas Powles, Tibor Csoszi, Mustafa Ozguroglu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol 2021;22:931-41
不详
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (05): : 854 - 854
[37] Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
Garcia-Donas, Jesus
Font, Albert
Perez-Valderrama, Begona
Antonio Virizuela, Jose
Angel Climent, Miquel
Hernando-Polo, Susana
Angel Arranz, Jose
del Mar Llorente, Maria
Lainez, Nuria
Carlos Villa-Guzman, Jose
Mellado, Begona
Gonzalez del Alba, Aranzazu
Castellano, Daniel
Gallardo, Enrique
Anido, Urbano
Garcia del Muro, Xavier
Domenech, Montserrat
Puente, Javier
Morales-Barrera, Rafael
Luis Perez-Gracia, Jose
Bellmunt, Joaquim
LANCET ONCOLOGY, 2017, 18 (05): : 672 - 681
[38] Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
von Minckwitz, Gunter
Puglisi, Fabio
Cortes, Javier
Vrdoljak, Eduard
Marschner, Norbert
Zielinski, Christoph
Villanueva, Cristian
Romieu, Gilles
Lang, Istvan
Ciruelos, Eva
De laurentiis, Michele
Veyret, Corinne
de Ducla, Sabine
Freudensprung, Ulrich
Srock, Stefanie
Gligorov, Joseph
LANCET ONCOLOGY, 2014, 15 (11): : 1269 - 1278
[39] Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Guo, Y.
Ahn, M-J
Chan, A.
Wang, C-H
Kang, J-H
Kim, S-B
Bello, M.
Arora, R. S.
Zhang, Q.
He, X.
Li, P.
Dechaphunkul, A.
Kumar, V
Kamble, K.
Li, W.
Kandil, A.
Cohen, E. E. W.
Geng, Y.
Zografos, E.
Tang, P. Z.
ANNALS OF ONCOLOGY, 2019, 30 (11) : 1831 - 1839
[40] Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Machiels, Jean-Pascal H.
Haddad, Robert I.
Fayette, Jerome
Licitra, Lisa F.
Tahara, Makoto
Vermorken, Jan B.
Clement, Paul M.
Gauler, Thomas
Cupissol, Didier
Jose Grau, Juan
Guigay, Joel
Caponigro, Francesco
de Castro, Gilberto, Jr.
Viana, Luciano de Souza
Keilholz, Ulrich
del Campo, Joseph M.
Cong, Xiuyu Julie
Ehrnrooth, Eva
Cohen, Ezra E. W.
LANCET ONCOLOGY, 2015, 16 (05): : 583 - 594

← 1 2 3 4 5 →